A diabetic patient with CKD stage 3b (eGFR 35 mL/min/1.73m²) and heart failure is started on an SGLT2 inhibitor. Which sub-mechanism specifically explains the cardiorenal protective effect independent of glucose lowering?

• A Direct inhibition of RAAS at the renal level by blocking angiotensinogen synthesis in proximal tubular cells
• B Activation of PPAR-gamma in podocytes, reducing proteinuria through increased nephrin expression
• C Stimulation of erythropoietin synthesis, improving cardiac oxygen delivery and reducing left ventricular wall stress
• D Restoration of tubuloglomerular feedback by reducing proximal tubular glucose/sodium reabsorption, decreasing intraglomerular pressure and hyperfiltration; simultaneously reducing cardiac preload and afterload via natriuresis and osmotic diuresis ✓

Explanation

SGLT2 inhibitors reduce proximal tubule reabsorption of filtered glucose and sodium. The increased sodium delivered to the macula densa restores the blunted tubuloglomerular feedback (TGF) present in diabetic hyperfiltration, causing afferent arteriole constriction and reducing intraglomerular pressure — the core renoprotective mechanism. The natriuretic and osmotic diuretic effects reduce plasma volume, preload, afterload, and sympathetic activation, explaining the heart failure benefit seen in EMPA-REG OUTCOME, DAPA-HF, and CREDENCE trials, even in non-diabetic patients. EPO induction is a minor additional effect but not the primary mechanism.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.